Ready to partner - PubMed (original) (raw)

Ready to partner

Mark X Sliwkowski. Nat Struct Biol. 2003 Mar.

No abstract available

PubMed Disclaimer

Similar articles

• Control of ErbB signaling through metalloprotease mediated ectodomain shedding of EGF-like factors.
  Sanderson MP, Dempsey PJ, Dunbar AJ. Sanderson MP, et al. Growth Factors. 2006 Jun;24(2):121-36. doi: 10.1080/08977190600634373. Growth Factors. 2006. PMID: 16801132 Review.
• The oncogenic ErbB-2/ErbB-3 heterodimer is a surrogate receptor of the epidermal growth factor and betacellulin.
  Pinkas-Kramarski R, Lenferink AE, Bacus SS, Lyass L, van de Poll ML, Klapper LN, Tzahar E, Sela M, van Zoelen EJ, Yarden Y. Pinkas-Kramarski R, et al. Oncogene. 1998 Mar 12;16(10):1249-58. doi: 10.1038/sj.onc.1201642. Oncogene. 1998. PMID: 9546426
• Signaling through ERBB receptors: multiple layers of diversity and control.
  Warren CM, Landgraf R. Warren CM, et al. Cell Signal. 2006 Jul;18(7):923-33. doi: 10.1016/j.cellsig.2005.12.007. Epub 2006 Feb 7. Cell Signal. 2006. PMID: 16460914 Review.
• Heregulin-dependent translocation and hyperphosphorylation of ErbB-2.
  Zhou W, Carpenter G. Zhou W, et al. Oncogene. 2001 Jun 28;20(29):3918-20. doi: 10.1038/sj.onc.1204517. Oncogene. 2001. PMID: 11439355
• Regulation of ErbB receptor signalling in cancer cells by microRNA.
  Barker A, Giles KM, Epis MR, Zhang PM, Kalinowski F, Leedman PJ. Barker A, et al. Curr Opin Pharmacol. 2010 Dec;10(6):655-61. doi: 10.1016/j.coph.2010.08.011. Epub 2010 Sep 21. Curr Opin Pharmacol. 2010. PMID: 20864407 Review.

Cited by

• Application and challenge of HER2DX genomic assay in HER2+ breast cancer treatment.
  Ma S, Zhou Y, Ma D, Qi X, Jiang J. Ma S, et al. Am J Cancer Res. 2024 Sep 15;14(9):4218-4235. doi: 10.62347/JWHA6355. eCollection 2024. Am J Cancer Res. 2024. PMID: 39417184 Free PMC article. Review.
• The impact of nitric oxide on HER family post-translational modification and downstream signaling in cancer.
  O'Neill CE, Sun K, Sundararaman S, Chang JC, Glynn SA. O'Neill CE, et al. Front Physiol. 2024 Mar 27;15:1358850. doi: 10.3389/fphys.2024.1358850. eCollection 2024. Front Physiol. 2024. PMID: 38601214 Free PMC article. Review.
• Molecular Targeting of the Human Epidermal Growth Factor Receptor-2 (HER2) Genes across Various Cancers.
  Rubin E, Shan KS, Dalal S, Vu DUD, Milillo-Naraine AM, Guaqueta D, Ergle A. Rubin E, et al. Int J Mol Sci. 2024 Jan 15;25(2):1064. doi: 10.3390/ijms25021064. Int J Mol Sci. 2024. PMID: 38256137 Free PMC article. Review.
• MicroRNAs as biomarkers for trastuzumab-based therapy in HER2-positive advanced oesophago-gastric cancer patients.
  Lote H, Mousoullou F, Vlachogiannis G, Lampis A, Satchwell L, Peckitt C, Fong C, Begum R, Kidd S, Cromarty S, Gordon A, Fribbens C, Rao S, Starling N, Chau I, Cunningham D, Valeri N. Lote H, et al. Front Oncol. 2023 Nov 29;13:1258365. doi: 10.3389/fonc.2023.1258365. eCollection 2023. Front Oncol. 2023. PMID: 38094609 Free PMC article.
• From Anti-HER-2 to Anti-HER-2-CAR-T Cells: An Evolutionary Immunotherapy Approach for Gastric Cancer.
  Sun J, Li X, Chen P, Gao Y. Sun J, et al. J Inflamm Res. 2022 Jul 17;15:4061-4085. doi: 10.2147/JIR.S368138. eCollection 2022. J Inflamm Res. 2022. PMID: 35873388 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations